Cartesian Therapeutics, Inc. (RNAC) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
| Previous Close | 10.23 |
| Open | 10.36 |
| Day High | 10.36 |
| Day Low | 10 |
| 52-Week High | 11.39 |
| 52-Week Low | 5.6 |
| Volume | 163,914 |
| Average Volume | 268,756 |
| Market Cap | 294.99M |
| PE | -2.67 |
| EPS | -3.76 |
| Moving Average 50 Days | 8.98 |
| Moving Average 200 Days | 7.57 |
| Change | -0.19 |
Cartesian Therapeutics Highlights Recent Progress and Outlines 2026 Outlook
GlobeNewswire Inc.
Jan 09, 2026 1:04 PM GMT
Enrollment on track in Phase 3 AURORA trial of Descartes-08 in myasthenia gravis IND application for Descartes-08 in myositis accepted by FDA; seamless adaptive clinical trial offering potential opportunity for a single pivotal trial expected to com
Cartesian Therapeutics Announces the Appointment of Adrian Bot to Board of Directors
GlobeNewswire Inc.
Dec 18, 2025 9:05 PM GMT
FREDERICK, Md., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced the appointment of Adrian Bot, M.
Cartesian Therapeutics Announces Strong Efficacy Signal in Phase 2 Trial of Descartes-08 in Patients with SLE and Expansion of Clinical Development into Myositis
GlobeNewswire Inc.
Nov 13, 2025 9:05 PM GMT
100% LLDAS response rate observed in patients with SLE who received Descartes-08 in Phase 2 open-label trial reaching Month 3 follow-up (n=3) Disease remission reported as DORIS response seen in 2 out of 3 patients reaching Month 3 follow-up (n=3) D